These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 39212926)

  • 1. Immunotherapy in Gastrointestinal Cancers.
    Lote H; Chau I
    Cancer Treat Res; 2024; 192():277-303. PubMed ID: 39212926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.
    Mendis S; Gill S
    Curr Oncol; 2020 Apr; 27(Suppl 2):S59-S68. PubMed ID: 32368175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Gastrointestinal Malignancies.
    Mizrahi J; Pant S
    Adv Exp Med Biol; 2020; 1244():93-106. PubMed ID: 32301012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
    Abdul-Latif M; Townsend K; Dearman C; Shiu KK; Khan K
    Cancer Treat Rev; 2020 Aug; 88():102030. PubMed ID: 32505807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in immunotherapy for gastrointestinal tract cancers.
    Chong X; Madeti Y; Cai J; Li W; Cong L; Lu J; Mo L; Liu H; He S; Yu C; Zhou Z; Wang B; Cao Y; Wang Z; Shen L; Wang Y; Zhang X
    J Hematol Oncol; 2024 Aug; 17(1):65. PubMed ID: 39123202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of immunotherapy in gastrointestinal malignancies.
    Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
    Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
    Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
    Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
    Gervaso L; Ciardiello D; Oliveira RA; Borghesani M; Guidi L; Benini L; Algeri L; Spada F; Zampino MG; Cella CA; Fazio N
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
    Salem ME; Puccini A; Grothey A; Raghavan D; Goldberg RM; Xiu J; Korn WM; Weinberg BA; Hwang JJ; Shields AF; Marshall JL; Philip PA; Lenz HJ
    Mol Cancer Res; 2018 May; 16(5):805-812. PubMed ID: 29523759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for immune therapy in gastrointestinal cancers.
    Weinberg BA; Hameed R; Marshall JL
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
    Hsu A; Mendelson L; Almhanna K
    R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.
    Shimozaki K; Nakayama I; Hirota T; Yamaguchi K
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.
    Myint ZW; Goel G
    J Hematol Oncol; 2017 Apr; 10(1):86. PubMed ID: 28434400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.
    Stein A; Moehler M; Trojan J; Goekkurt E; Vogel A
    Crit Rev Oncol Hematol; 2018 Oct; 130():13-26. PubMed ID: 30196908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.